You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020215015
Dec 202047011
Jan 202124013
Feb 20215007
Mar 20219008
Apr 202170010
May 202122021
Jun 20210027
Jul 20210018
Aug 2021008
Sep 20210010
Oct 202186038
Nov 2021101037
Dec 20213806
Jan 20223405
Feb 20225606
Mar 202284021
Apr 20226203
May 20226603
Jun 20229607
Jul 20229004
Aug 20225609
Sep 202272010
Oct 20227205
Nov 20225405
Dec 20224400
Jan 20233001
Feb 20236405
Mar 20236006
Apr 20236408
May 20236805
Jun 20236209
Jul 20234007
Aug 20235306
Sep 20233803
Oct 20234204
Nov 20235206
Dec 20236004
Jan 20243601
Feb 20244005
Mar 20247406
Apr 20244406
May 20244806
Jun 20243203
Jul 202450013
Aug 20242203
Sep 20245003
Oct 20242808
Nov 20245406
Dec 202446014
Jan 20254408
Feb 20252203
Mar 20250013
Apr 2025004
May 2025009
Jun 2025007
Total27520489